EUVIMEDEUVIMED entdecken
Crossref

A Validated Quantitative LC–MS/MS Method for Determination of Deucravacitinib in Rat Plasma and Its Application to a Pharmacokinetic Study

Pottabattula Mahesh, M Akiful Haque iD

Biomedical Chromatography · 2025

DOI: 10.1002/bmc.70169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Pottabattula Mahesh und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Anurag University, Hyderabad, Telangana, India. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We developed and validated a novel analytical methodology for the precise quantification of deucravacitinib, an oral TYK2 inhibitor for treating moderate‐to‐severe plaque psoriasis in adults. Liquid chromatography–tandem mass spectrometry (LC–MS/MS) was employed in this method for sensitive detection of the compound in rat plasma. Analytical separation was performed utilizing an ACE C18 column (4.6 × 100 mm, 5‐μm particle size) with a carefully optimized mobile phase composition of methanol and 2‐mM ammonium formate (90:10, v/v), maintained at a consistent flow rate of 0.9 mL/min. Detection was executed in positive ionization mode, targeting multiple reaction monitoring (MRM) transitions of m/z 426.8 → 358.4 for the analyte and m/z 394.1 → 363.2 for the internal standard. The validation of the analytical method encompassed an assessment of selectivity, linearity, accuracy, precision, recovery, and stability. This method demonstrated stability, specificity, and no matrix effect at three concentration levels (1.606, 267.600, 507.780 ng/mL). The method's lower limit of quantification (LLOQ) is 0.556 ng/mL. The calibration curve demonstrates linearity from the LLOQ up to 668.132 ng/mL, exhibiting a high correlation coefficient ( r 2 = 0.9976). The intraday and interday precisions were less than 6.62% and 5.95%, respectively, with accuracies ranging from 90.68% to 103.80%. The recovery of deucravacitinib ranged from 95.34% to 103.80% and remained stable under different conditions. After successful validation, the method was used for pharmacokinetic profiling of deucravacitinib in rats following oral administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tandem Mass SpectrometryAnimalsRatsReproducibility of ResultsChromatography, LiquidLinear ModelsMaleRats, Sprague-DawleyLimit of DetectionSensitivity and SpecificityDrug StabilityLiquid Chromatography-Mass Spectrometry

Stichwörter der Autor:innen

LC–MS/MSdeucravacitinibmethod validationpharmacokineticspsoriasisrat plasma

Autor:innen und Institutionen

  • School of Pharmacy, Anurag University, Hyderabad, Telangana, India.

ORCID-Profile: M Akiful Haque

Zitieren

APA

Mahesh, P., & Haque, M. A. (2025). A Validated Quantitative LC–MS/MS Method for Determination of Deucravacitinib in Rat Plasma and Its Application to a Pharmacokinetic Study. Biomedical Chromatography. https://doi.org/10.1002/bmc.70169

Vancouver

Mahesh P, Haque MA. A Validated Quantitative LC–MS/MS Method for Determination of Deucravacitinib in Rat Plasma and Its Application to a Pharmacokinetic Study. Biomedical Chromatography. 2025. doi:10.1002/bmc.70169

BibTeX
@article{Mahesh2025,
  author = {Mahesh, Pottabattula and Haque, M Akiful},
  title = {A Validated Quantitative LC–MS/MS Method for Determination of Deucravacitinib in Rat Plasma and Its Application to a Pharmacokinetic Study},
  journal = {Biomedical Chromatography},
  year = {2025},
  doi = {10.1002/bmc.70169}
}
Kostenlos starten →